ArticleViruses2016
Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus.
Article in Viruses, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Memory Cell and Antibody Responses Following a Single Versus Two Doses of Escherichia coli-Produced Vaccine Against Human Papillomavirus Types 16 and 18: A Real-World Study in Chinese Girls.International journal of cancer · 2026Article
- Article
- Immunogenicity comparison of anThe Lancet regional health. Western Pacific · 2025Article
- Article
- Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests.NPJ vaccines · 2025Article
- Rational design of a triple-type HPV53/56/66 vaccine with one preferable base particle incorporating two identified immunodominant sites.Journal of nanobiotechnology · 2025Article
- Assessment of the ability of HPV vaccines to induce neutralizing antibodies based on pseudovirus-based neutralization assay.Frontiers in public health · 2025Article
- HPV-specific antibodies in female genital tract secretions captured via first-void urine retain their neutralizing capacity.Human vaccines & immunotherapeutics · 2024Article
- A Preclinical Immunogenicity Study of the Recombinant Human Papillomavirus Nine-Valent Virus-like Particle Vaccine.Vaccines · 2024Article
- A Comprehensive Evaluation of the HPV Neutralizing Antibodies in Guangzhou, China: A Comparative Study on Various HPV Vaccines.Vaccines · 2024Article
- Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice.Vaccines · 2024Article
- WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58.NPJ vaccines · 2024Article
- Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector.Emerging microbes & infections · 2023Article
- Safety and immunogenicity of anThe Lancet regional health. Western Pacific · 2023Article
- The second HPV serology meeting: Progress and challenges in standardization of human papillomavirus serology assays.Vaccine · 2023Article
- Application of Pseudotyped Viruses.Advances in experimental medicine and biology · 2023Review
- Pseudotyped Virus for Papillomavirus.Advances in experimental medicine and biology · 2023Article
- Pseudotyped Viruses for Lyssavirus.Advances in experimental medicine and biology · 2023Article
- Assays Based on Pseudotyped Viruses.Advances in experimental medicine and biology · 2023Article
- Construction and applications of SARS-CoV-2 pseudoviruses: a mini review.International journal of biological sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudovirion-based neutralization assay is considered the gold standard method for evaluating the immune response to human papillomavirus (HPV) vaccines. In this study, we developed a multicolor neutralization assay to simultaneously detect the neutralizing antibodies against different HPV types. FluoroSpot was used to interpret the fluorescent protein expression instead of flow cytometry. The results of FluoroSpot and flow cytometry showed good consistency, with R² > 0.98 for the log-transformed IC50 values. Regardless of the reporter color, the single-, dual-, and triple-color neutralization assays reported identical results for the same samples. In low-titer samples from naturally HPV-infected individuals, there was strong agreement between the single- and triple-color assays, with kappa scores of 0.92, 0.89, and 0.96 for HPV16, HPV18, and HPV58, respectively. Good reproducibility was observed for the triple-color assay, with coefficients of variation of 2.0%-41.5% within the assays and 8.3%-36.2% between the assays. Three triple-color systems, HPV16-18-58, HPV6-33-45, and HPV11-31-52, were developed that could evaluate the immunogenicity of a nonavalent vaccine in three rounds of the assay. With the advantages of an easy-to-use procedure and less sample consumption, the multiple-color assay is more suitable than classical assays for large sero-epidemiological studies and clinical trials and is more amenable to automation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.